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Abstract 
Review on MCM3, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: HCC5, P1-MCM3, P1.h, RLFB 
HGNC (Hugo): MCM3 
Location: 6p12.2 
DNA/RNA 
Description 
The human MCM3 gene is located on the minus 
strand and spans 20868 bps of genomic region 
(52264014-52284881). This gene has 7 transcripts 
(splice variants). It has 853 amino acids and its size 
is about 91 kDa. It contains a nuclear localization 
signal and possess an ATPase/helicase region at the 
centre. It has a total of 17 exons and extends a bit 
more than 20 KB of genomic DNA. (Hofmann et 
al., 2000) (Fig. 1). 
Transcription 
There are two transcript variants encoding different 
isoforms known for MCM3. These are transcript 
variant 1 (accession number NM_002388.4) and 
transcript variant 2 (NM_001270472.1). The 
transcript variant 2 lacks an alternate exon 
compared to transcript variant 1. MCM3 gene has 
been observed to be expressed highly in different 
cancer cell lines as compared to normal tissues (Ha 
et al., 2004). Higher mRNA expression of MCM3 
was also shown to be linked with papillary thyroid 
carcinoma (PTC) (Igci et al., 2014). The expression 
level of MCM3 is also increased in cell lines 
overexpressing E2F, suggesting that MCM3 is also 
target of E2F (Leone et al., 1998; Bruemmer et al., 
2003). 
Pseudogene 
There is no known pseudogene for MCM3. 
Protein 
Description 
The protein encoded by MCM3 gene is known to 
be a well conserved mini-chromosome maintenance 
protein (MCM) which is needed for triggering the 
eukaryotic genome replication.  
It acts as DNA replication licensing factor.  
The well known other synonym for this protein is 
DNA polymerase alpha holoenzyme-associated 
protein P1 due to its indispensable role in DNA 
replication and cell proliferation and also 
participates in the control of genome duplication 
during cell cycle. The MCM3 protein is composed 
of 808 amino acid residues, having molecular mass 
of approximately 91 kDa and a basal isoelectric 
point of 5.53.The MCM3 protein is subunit of the 
protein complex (MCM 2-7) i.e the 
minichromosome maintenance (MCM) complex. It 
contains active ATPase sites which supplement to 
the helicase activity needed during DNA 
replication. MCM3 protein contains 8 nucleotide 
length region that binds nucleotide phosphates. 
(Fig. 2). 
MCM3AP (Minichromosome Maintenance-3 
Associated Protein) interacts and acetylates MCM3 
protein inhibiting cell cycle progression.  
MCM3 (minichromosome maintenance complex component 
3) 
Arman K, et al. 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(10) 612 
 
 
Figure 1. MCM3 gene location, the representation of two major splice variants, and the depiction of major motifs. 
 
 
There is an interaction between MCM3 and 
MCM3AP which is required for nuclear 
localization and chromatin binding of MCM3AP 
(Takei et al., 2002). The acetylase activity of 
MCM3AP is known to inhibit only initiation of 
DNA replication and does not inhibit its elongation 
(Takei et al., 2002). MCM3 are known to have 
distinguishable nuclear localization sequences 
(NLS), indicating that these MCMs help in 
providing nuclear targeting to different other 
members of the MCM family (Kimura et al., 1996; 
Forsburg, 2004). 
Like other MCM proteins, MCM3 is a member of 
the AAA+ class of ATPases. It contains binding 
site for ATP, Walker A motif, Walker B motif and 
arginine motif. AAA+ ATPases usually form ATP-
dependent complexes usually heterohexamers. The 
structure of MCM3 includes the MCM box 
spanning about 200 residues. This peculiar MCM 
box has two ATPase consensus domains or motifs. 
One of them is the Walker A domain which 
includes the active site with P-loop. In Walker A 
consensus, glycine is replaced by alanine or serine 
along with many other conserved residues, 
eventually forming the MCM-specific region 
GDPxx(S/A)KS (Forsburg, 2004). Other is the 
classic Walker B which is hydrophobic in nature 
that is primarily responsible for the hydrolysis of 
ATP rather than binding. Like all the MCM 
proteins, the Walker B motif of MCM3 possess the 
conserved sequence IDEFDKM that distinguishes 
the MCM family. There is also presence of a short 
motif, SRFD that is present about 70 residues 
following the Walker B element, constitutes an 
"arginine finger". Infact all other MCMs also 
contain these sequences. 
The MCM3 also possesses a zinc finger residing 
prior to the MCM box that somewhat matches a 
classic zinc finger region, but has been stated that 
the residues are capable of chelating zinc (Fletcher 
et al., 2003).  
Biochemical analysis also revealed that the zinc 
motif aids in formation of complex assembly as 
well as ATPase activity (Poplawski et al., 2001; 
Fletcher et al., 2003). Members of the AAA+ 
ATPases are well known to function as molecular 
chaperons. The AAA+ proteins possess several 
distinct characteristics. The formation of active 
ATPase sites in the MCM2-7 ring takes place via 
interacting surfaces of two adjacent subunits. This 
interaction occurs in such a way that the conserved 
arginine finger motif resides in trans relative to the 
Walker A box (ATP-binding site) of the of the 
adjacent subunit. 
Expression 
Despite an increase in transcription for some MCM 
genes during the G1/S phase in dividing cells, 
MCM3 protein levels remain constant during the 
cell cycle (Forsburg et al., 1997; Diffley and Labib, 
2002). MCM3 protein is found to have nuclear 
expression in all in proliferating cells. There is high 
expression of MCM3 proteins in trophoblastic cells 
of placenta, hematopoietic cells of bone marrow. 
But it has not been detected in decidual cells of 
placenta, brain, liver, kidney, ovary, spleen, lung, 
skeletal muscles, smooth muscles and heart 
muscles.  
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Figure 2. MCM3 protein sequence showing AAA region (blue coloured), ATP binding site (blue colour underlined), Walker A 
motif (highlighted with yellow color), Walker B motif (highlighted with grey color), SRFD arginine finger motif (red). 
 
 
This DNA replication licensing factor is also 
expressed at lower intensity in many other cell 
types, including squamous epithelial cells of 
oesophagus, glandular cells of appendix and breast, 
urothelial cells of the urinary bladder, respiratory 
epithelial cells of nasopharynx. 
Localisation 
The MCM3 protein is localized to the nucleus. 
Function 
MCM3 protein is extremely conserved mini-
chromosome maintenance proteins (MCM) in 
eukaryotes and is ubiquitously expressed. MCM3 is 
one of the members of MCM family with 
chromatin-binding proteins. MCM3 by acting as an 
indispensable factor permits a single round of 
replication of DNA per cell cycle. It is responsible 
for the initiation of eukaryotic genome replication 
and cell proliferation and monitors the cell cycle 
control of genome duplication. MCM3 gene 
encodes P1 protein which has a role in the DNA 
replication process. 
MCM3 protein is part of the protein complex 
consisting of MCM2-7. It participates in the 
formation of the heterohexameric MCM complex, 
which is loaded onto the chromatin at sites of DNA 
replication, leading to the formation of pre-
replication complex (pre-RC). The proteins that 
compose the MCM complex also serve as DNA 
helicases that unwind the DNA double helix at the 
replication forks apart from the initiation of 
replication. Furthermore, MCM3 actively 
participates in cell cycle regulation. The MCM3 is 
responsible for genome stability, as it limits the 
replication to only once per cell cycle. 
MCMs have a direct role in transcription. There are 
several evidences suggesting that the MCM 
proteins do associate with specific transcription 
factors. Mcm3-Mcm5 complex forms a heterodimer 
associating with STAT1a (a transcription factor) 
during biochemical purification (Zhang et al., 1998; 
DaFonseca et al., 2001). Infact MCM5 mediates 
this association. MCM3, MCM2 and MCM5 form 
the peripheral subunits of the complex that is 
known to negatively regulate the active MCM core 
subunits (MCM4, MCM6 and MCM7). It is known 
to interact directly with MCM5/CDC46. The well 
known MCM3 acetylating protein, MCM3AP (a 
chromatin-associated acetyltransferase) binds and 
acetylates MCM3 further inhibiting the initiation of 
DNA replication including cell cycle progression. 
It has been shown that there is a functional 
interaction between two important moieties i.e the 
glucocorticoid receptor and GANP (germinal 
center-associated protein)/MCM3AP. GANP and 
MCM3AP are known to bind to the MCM3 protein 
which is involved in triggering of DNA replication 
(Osman et al., 2006). It is shown that cyclin E/Cdk2 
phosphorylates MCM3 at a particular site i.e 
Thr722, regulating the loading of MCM3 onto 
chromatin and thus controls S phase checkpoint (Li 
et al., 2011). Mcm3, Mcm2 and Mcm4 show cell 
cycle specific phosphorylation that relates to 
chromatin binding. They are shown to be 
hypophosphorylated and chromatin-bound in G1 
which eventually gets phosphorylated by Cdk 
activity at G1/S and later in the cell cycle (Fujita et 
al., 1998). Phosphorylation of Mcm proteins is also 
needed for pre-RC assembly and activation which 
is dependent on Cdk activity and Cdc7-Dbf4 kinase 
is also required (Sato et al., 1997; Weinreich and 
Stillman, 1999; Masai et al., 2000). In summary, 
the molecular function of MCM3 includes DNA 
helicase activity, DNA binding, protein binding and 
ATP binding while the biological processes of 
MCM3 includes DNA replication initiation, DNA 
strand elongation, mitotic cell cycle, DNA 
replication, DNA duplex unwinding, G1/S 
transition during mitotic cell cycle. 
Homology 
The gene encoding the human P1 protein (MCM3) 
has 60% homology to the yeast MCM3 
(minichromosome maintenance deficiency) 
replication control gene of S. cerevisiae (Thommes 
et al., 1992). In another study it has been observed 
that MCM3 shares three central regions of high 
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sequence similarity i.e about 75% as well as highly 
hydrophilic carboxy-terminal region with the 
Mcm3 replication protein of the yeast (Schulte et 
al., 1995). MCM3 is also homologous to other 
MCM complex components (MCM2, MCM5, 
MCM6, MCM7) and can form several kind of 
heteromeric complexes. Mutants defective in 
MCM2 or MCM3 are extremely similar in 
phenotype. They both possess an autonomously 
replicating sequence (ARS)-specific 
minichromosome maintenance defect, however 
their ARS specificities are not identical. MCM3 
resembles MCM2 as they both contain NLS 
(Nuclear localization sequences) and are involved 
in translocating the complex from the cytoplasm to 
the nucleus (Gozuacik et al., 2003). 
Mutations 
A nuclear localization signal of human MCM3 has 
been clarified and being established that 
mutagenesis on the nuclear localization signal of 
MCM3 affects the binding of newly isolated 
MCM3-assosiated protein, Map80 (Takei and 
Tsujimoto, 1998). In Saccharomyces cerevisiae, 
two mutant alleles i.e mcm3-1 and mcm3-10 that 
are defective at different steps of the replication 
initiation process have been characterized (Lei et 
al., 2002). Both Mcm3-10 and Mcm3-1 have 
defectiveness with regard to the recruitment of the 
MCM2-7 complex to replication origins. Mcm3-10 
affects a step before, and Mcm3-1 affects a step 
after the recruitment of the MCM2-7 complex to 
replication origins. Mcm3-1 has a G246E mutation 
that lessens the efficiency of replication initiation 
(Yan et al., 1993). 
Implicated in 
Uterine cervical cancer 
It has been shown that MCM3 is ubiquitously 
expressed in cancer cells by immunohistochemical 
studies of surgical materials from human uterine. 
Moreover, cancerous cells has higher MCM3 
expression than in normal proliferating cells of the 
uterine cervix and dysplastic cells, making it a 
useful marker to differentiate these cells (Ishimi et 
al., 2003). These results indicate that the malignant 
transformation of cells is directly related to the 
higher expression of MCM3 protein. 
Papillary thyroid carcinoma 
Papillary thyroid carcinoma (PTC) is known to be 
the most common histological type among the other 
types which accounts for up to 80 % of the total 
thyroid cancer cases (Fagin and Mitsiades, 2008). It 
has been shown that the MCM3 protein expression 
levels were overexpressed in papillary thyroid as 
compared to normal thyroid tissues through 
immunohistochemical analysis and Western blot 
analysis (Lee et al., 2010). A comparative study of 
MCM3 protein expression levels was also done in 
follicular variant of papillary thyroid carcinoma 
(FVPTC), classic variant of papillary thyroid 
carcinoma (CVPTC), and multi-nodular goitre 
(MNG) tissues. MCM3 protein expression was 
higher in FVPTC and CVPTC as compared to 
MNG (Igci et al., 2011; Igci et al., 2014). This 
shows that MCM3 might be used as a suitable 
marker in order to distinguish FVPTC and CVPTC 
from MNG. 
Brain malignancies 
MCM3 shows a restricted immune response by 
cancer in patients with brain malignancies. It is a 
strong predictor of survival in patients with 
anaplastic astrocytoma (Soling et al., 2005). MCM3 
has been shown to have higher expression in human 
astrocytic tumors and highlights a cancer-restricted 
humoral immune response in patients with brain 
tumors and brain metastases but not in healthy 
controls. MCM3 expression in diffuse astrocytoma 
is found to be significantly associated with age, 
histologic grade, time to recurrence (Soling et al., 
2005). 
Endometrial carcinogenesis 
The expression of MCM3 in endometrial 
carcinomas was shown to be significantly lower 
than the normal proliferative endometrium. The 
expression of MCM3 also differs according to the 
phases. It is significantly higher in the proliferative 
phase than in the secretory phase. The above 
observations show that the expression of MCM3 
reflects cell proliferation in normal and hyperplastic 
endometria (Kato et al., 2003). The replication-
licensing system may be aberrant in endometrial 
carcinomas as there is an inconsistency between the 
expression of MCMs and cell proliferation in 
endometrial carcinomas. 
Salivary gland tumors 
MCM3 was significantly higher in mucoepidermoid 
carcinomas (MEC) and adenoid cystic carcinomas 
(ADCC) with respect to pleomorphic adenomas 
(PA). A high sensitivity and specificity for MCM3 
was obtained to differentiate benign and malignant 
tumors (Ashkavandi et al., 2013). 
Other malignancies 
Minichromosome maintenance 3 (MCM3) gene 
was highly expressed in a lot of human cancers, like 
lymphoma, leukemia, carcinomas of the uterine 
cervix, stomach, breast, kidney and lung, malignant 
melanoma as well as benign and malignant 
melanocytic skin lesions (Ha et al., 2004; 
Gambichler et al., 2009). MCM3 protein was also 
found to be upraised in several human cancer 
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tissues analysed by western blot and 
immunohistochemical analyses (Ha et al., 2004). 
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